Values as of: 2024-12-28
COMMON STOCK | Biotechnology |
Last Closing
USD 214.34Change
0.00 (0.00)%Market Cap
USD 13.91BVolume
2.00KAnalyst Target
N/AVerdict
Verdict
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 36.93B |
| UCBJY | UCB SA ADR |
N/A |
USD 36.22B |
| UCBJF | UCB SA |
N/A |
USD 36.22B |
| WXIBF | WuXi Biologics |
N/A |
USD 10.26B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 9.12B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 8.24B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 8.01B |
| IVBIY | IVBIY |
N/A |
USD 7.83B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.73B |
| AKESF | Akeso, Inc. |
N/A |
USD 7.54B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -32.11% | 47% | F | 32% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -32.11% | 47% | F | 31% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -32.11% | 47% | F | 32% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -32.11% | 47% | F | 31% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -0.92% | 78% | C+ | 65% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -0.92% | 78% | C+ | 57% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 1.38% | 49% | F | 40% | F | ||
| Dividend Return | 1.38% | 49% | F | 36% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 31.14% | 88% | B+ | 71% | C- | ||
| Risk Adjusted Return | 4.42% | 51% | F | 37% | F | ||
| Market Capitalization | 13.91B | 99% | N/A | 93% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
